LAUSR

Abstract Background: We aimed to conduct a meta-analysis to assess the effect of pharmaceutical care on the treatment of coronavirus disease 2019 (COVID-19). Methods: All case-controlled studies related to pharmaceutical care on the treatment of COVID-19 will be included in this review. We will use index words related to pharmaceutical care and COVID-19 to perform literature searches in PubMed, Embase, MEDLINE, CNKI, and Wanfang databases, to include articles indexed as of October 20, 2020 in English and Chinese language. Two reviewers will select trials independently for inclusion and assess trial quality. Two pairs of review authors will independently extract information for each included trials. Primary outcomes are clinical outcomes, average hospital stays, costs, patient satisfaction, and incidence of adverse drug reactions. We will evaluate the risk of bias of the included studies based on Cochrane assessment tool. Revman 5.3 (the Cochrane collaboration, Oxford, UK) will be used for heterogeneity assessment, generating funnel-plots, data synthesis, subgroup analysis, and sensitivity analysis. Results: We will provide targeted and practical results assessing the effect of pharmaceutical care on the treatment of COVID-19. Conclusion: The stronger evidence about the effect of pharmaceutical care on the treatment of COVID-19 will be provided for clinicians. Systematic review registration number: PROSPERO CRD42020214223 Ethics and dissemination: There is no need for ethical approval, and the review will be reported in a peer-reviewed journal.